, Volume 171, Issue 4, pp 465–471 | Cite as

Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment

Original Investigation



Chronic transdermal nicotine has been found to improve attentional performance in patients with Alzheimer’s disease (AD), but little is known about chronic nicotine effects in age-associated memory impairment (AAMI), a milder form of cognitive dysfunction. The current study was performed to determine the clinical and neuropsychological effects of chronic transdermal nicotine in AAMI subjects over a 4-week period.


The double-blind, placebo-controlled, cross-over study consisted of two 4-week periods separated by a 2-week washout period.


An outpatient setting was used.


The subjects (n=11) met criteria for AAMI.


The subjects were given nicotine patches (Nicotrol) to wear for 16 h a day at the following doses: 5 mg/day during week 1, 10 mg/day during week 2 and week 3 and 5 mg/day during week 4.


The effects of nicotine treatment were determined with the clinical global impressions questionnaire, Conners’ Continuous Performance test, and the automated neuropsychologic assessment metrics (ANAM) computerized neuropsychology battery.


Nicotine significantly improved the clinical global impression score as assessed by participants, as well as objective tests of attentional function on the Connors’ Continuous Performance Test and decision reaction time on the neuropsychology test battery. Nicotine did not improve performance on other tests measuring motor and memory function.


Chronic transdermal nicotine treatment in AAMI subjects caused a sustained improvement in clinical symptoms and objective computerized tests of attention. These results support the further investigation of nicotinic treatment as a promising therapy for AAMI.


Nicotine Age-associated memory impairment Attention Nicotine skin patches 



The authors thank Channelle Christopher for her help gathering data, the staff of the Duke University Geriatric Evaluation and Treatment Center for their logistic support and Pharmacia, Inc. for donating the nicotine patches and placebos. The abstract of this research was presented at the American College of Neuropsychopharmacology, San Juan, PR, December, 2002.


  1. Conners CK (1994) The continuous performance test (CPT): use as a diagnostic tool and measure of treatment outcome. Annual convention of the American Psychological Association, Los Angeles, CA, 12–16 August 1994Google Scholar
  2. Conners CK (1995) The continuous performance test. Multi-Health Systems, TorontoGoogle Scholar
  3. Crook T, Bartus T, Ferris S, Whitehouse P (1986) Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of a National Institute of Mental health work group. Dev Neurobiol 2:261–276Google Scholar
  4. Crook T, Feher E, Larrabee G (1992) Assessment of memory complaints in age-associated memory impairment: The MAC-Q. Int Psychogeriatr 4:165–175PubMedGoogle Scholar
  5. Epstein JN, Conners CK, Sitarenios G, Erhardt D (1998) Continuous performance test results of adults with attention deficit hyperactivity disorder. Clin Neuropsychol 12:155–168CrossRefGoogle Scholar
  6. Folstein M, Folstein S, McHugh P (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedGoogle Scholar
  7. Giacobini E, DeSarno P, McIlhany M, Clark B (1988) The cholinergic receptor system in the frontal lobe of Alzheimer’s patients. In: Clementi F, Gotti C, Sher E (eds) Nicotinic acetylcholine receptors in the nervous system. Springer, Berlin Heidelberg New York, pp 367–378Google Scholar
  8. Guy W (1976) Clinical global impressions. ECDEU assessment manual for psychopharmacology, revised edn. Department of Health, Education, and Welfare, Rockville, pp 218–222Google Scholar
  9. Howe M, Price I (2001) Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia. Int Psychogeriatr 13:465–475PubMedGoogle Scholar
  10. Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease. Psychopharmacology 108:485–494PubMedGoogle Scholar
  11. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, Sherman SE, Cleveland M, Antonnucio DO, Hartman N, McGovern PG (1996) The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335:1792–1798CrossRefPubMedGoogle Scholar
  12. Kellar KJ, Whitehouse PJ, Martino-Barrows AM, Marcus K, Price DL (1987) Muscarinic and nicotinic cholinergic binding sites in Alzheimer’s disease. Brain Res 436:62–68CrossRefPubMedGoogle Scholar
  13. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of nicotine on Parkinson’s disease. Brain Cogn 43:274–282Google Scholar
  14. Levin ED, Rezvani AH (2001) Nicotinic involvement in cognitive function in rats. In: Levin ED (ed) Nicotine and the nervous system. Methods in neuroscience. CRC Press, New YorkGoogle Scholar
  15. Levin E, Rezvani A (2002) The promise of nicotinic treatment for cognitive dysfunction. Curr Drug Targets 1:423–431Google Scholar
  16. Levin ED, Rose JE (1995) Acute and chronic nicotinic interactions with dopamine systems and working memory performance. In: Lajtha A, Abood L (eds) Functional diversity of interacting receptors. The New York Academy of Sciences, New York, pp 218–221Google Scholar
  17. Levin ED, Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138:217–230CrossRefPubMedGoogle Scholar
  18. Levin ED, Lee C, Rose JE, Reyes A, Ellison G, Jarvik M, Gritz E (1990) Chronic nicotine and withdrawal effects on radial-arm maze performance in rats. Behav Neural Biol 53:269–276PubMedGoogle Scholar
  19. Levin ED, Briggs SJ, Christopher NC, Rose JE (1992) Persistence of chronic nicotine-induced cognitive facilitation. Behav Neural Biol 58:152–158PubMedGoogle Scholar
  20. Levin E, Wilson W, Rose J, McEvoy J (1996a) Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15:429–436PubMedGoogle Scholar
  21. Levin ED, Conners CK, Sparrow E, Hinton S, Meck W, Rose JE, Ernhardt D, March J (1996b) Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123:55–63PubMedGoogle Scholar
  22. Levin ED, Conners CK, Silva D, Hinton SC, Meck W, March J, Rose JE (1998) Transdermal nicotine effects on attention. Psychopharmacology 140:135–141PubMedGoogle Scholar
  23. Levin ED, Conners CK, Silva D, Canu W, March J (2001) Effects of chronic nicotine and methylphenidate in adults with ADHD. Exp Clin Psychopharmacol 9:83–90Google Scholar
  24. Min S, Moon I, Ko R, Shin H (2001) Effects of transdermal nicotine on attention and memory in healthy elderly nonsmokers. Psychopharmacology 159:83–88CrossRefPubMedGoogle Scholar
  25. Newhouse PA, Kelton M (2000) Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. Pharm Acta Helv 74:91–101CrossRefPubMedGoogle Scholar
  26. Newhouse P, Potter A, Kelton M, Corwin J (2001) Nicotinic treatment of Alzheimer’s disease. Biol Psychiatry 49:268–278CrossRefPubMedGoogle Scholar
  27. Nordberg A (1994) Human nicotinic receptors—their role in aging and dementia. Neurochem Int 25:93–97CrossRefPubMedGoogle Scholar
  28. Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edwardson JA, Fairbairn A, Blessed G (1987) Nicotinic receptor abnormalities in Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psychiatry 50:806–809PubMedGoogle Scholar
  29. Provost SC, Woodward R (1991) Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology 104:536–540PubMedGoogle Scholar
  30. Reeves D, Bleiberg J, Spector J (1993a) Validation of the ANAM battery in multi-center head injury rehabilitation studies. Arch Clin Neuropsychol 8:356Google Scholar
  31. Reeves D, Kane R, Winter K, Raynsford K, Pancella T (1993b) Automated neuropsychological assessment metrics (ANAM): test administrator’s guide, version 1.0. Missouri Institute of Mental Health, St. Louis, MOGoogle Scholar
  32. Rusted J, Graupner L, Oconnell N, Nicholls C (1994) Does nicotine improve cognitive function? Psychopharmacology 115:547–549Google Scholar
  33. Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of Alzheimer type. Br J Psychiatry 154:797–800PubMedGoogle Scholar
  34. Seidl R, Tiefenthaler M, Hauser E, Lubec G (2000) Effects of transdermal nicotine on cognitive performance in Down’s syndrome. Lancet 356:1409–1410CrossRefPubMedGoogle Scholar
  35. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M (1986) Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 46:288–293PubMedGoogle Scholar
  36. Snaedal J, Johannesson T, Jonsson JE, Gylfadottir G (1996) The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer’s disease. Dementia 7:47–52PubMedGoogle Scholar
  37. Warburton DM, Arnall C (1994) Improvements in performance without nicotine withdrawal. Psychopharmacology 115:539–542PubMedGoogle Scholar
  38. Wesnes K, Revell A (1984) The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 84:5–11PubMedGoogle Scholar
  39. White HK, Levin ED (1999) Chronic four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease. Psychopharmacology 143:158–165PubMedGoogle Scholar
  40. Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, Kellar KJ (1988) Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 45:722–724PubMedGoogle Scholar
  41. Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, McFalls E, Kovera C, McCarten JR (1995a) Nicotine patches in Alzheimer’s disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 51:509–514PubMedGoogle Scholar
  42. Wilson AL, McCarten JR, Langley LK, Bauer T, Monley J, Rottunda S, McFalls E, Kovera C (1995b) Transdermal nicotine administration in Alzheimer’s disease: effects on cognition, behavior and cardiac function. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM (eds) Research advances in alzheimer’s disease and related disorders. John Wiley and Sons, Ltd., Chichester, pp 305–314Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Department of MedicineDuke University Medical CenterDurhamUSA
  2. 2.Department of Psychiatry and Behavioral SciencesDuke University Medical CenterDurhamUSA
  3. 3.Department of Pharmacology and Cancer BiologyDuke University Medical CenterDurhamUSA
  4. 4.Center for the Study of Aging and Human DevelopmentDuke University Medical CenterDurhamUSA
  5. 5.Geriatric ResearchEducation and Clinical Center, VAMCDurhamUSA

Personalised recommendations